Basit öğe kaydını göster

dc.contributor.authorDurur Subaşı, Irmak
dc.contributor.authorKöse, Duygu
dc.contributor.authorYayla, Muhammed
dc.contributor.authorŞirin, Büşra
dc.contributor.authorKaraman, Adem
dc.contributor.authorÇalık, İlknur
dc.contributor.authorAlper, Fatih
dc.date.accessioned2021-12-02T06:29:14Z
dc.date.available2021-12-02T06:29:14Z
dc.date.issued2021en_US
dc.identifier.citationDurur Subaşı, I., Köse, D., Yayla, M., Şirin, B., Karaman, A., Çalık, İ. ... Alper, F. (2021). Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats? European Radiology Experimental, 5(1). https://dx.doi.org/10.1186/s41747-021-00249-7en_US
dc.identifier.issn2509-9280
dc.identifier.urihttps://dx.doi.org/10.1186/s41747-021-00249-7
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8596
dc.description.abstractBackground We investigated whether levosimendan prevents contrast medium nephrotoxicity with glycerol aggravation in rats. Methods Forty-eight Wistar albino rats were assigned to eight groups (n = 6 x 8). No medication was administered to group I (controls); glycerol (intramuscular injection of 25% glycerol, 10 mL/kg) group II; intravenous iohexol 10 mL/kg to group III; glycerol and iohexol to group IV; iohexol and intraperitoneal levosimendan 0.25 mg/kg to group V; glycerol, iohexol, and levosimendan 0.25 mg/kg to group VI; iohexol and levosimendan 0.5 mg/kg to group VII; and glycerol, iohexol, and levosimendan 0.5 mg/kg to group VIII. One-day water withdrawal and glycerol injection prompted renal damage; iohexol encouraged nephrotoxicity; levosimendan was administered 30 min after glycerol injection and continued on days 2, 3, and 4. The experiment was completed on day 5. Serum blood urea nitrogen (BUN) and creatinine levels, superoxide dismutase (SOD) activity, glutathione (GSH), malondialdehyde (MDA) levels, tumour necrosis factor-alpha (TNF-alpha), nuclear factor kappa ss (NFK-ss), interleukin 6 (IL-6), and histopathological marks were assessed. One-way analysis of variance and Duncan's multiple comparison tests were used. Results Levosimendan changed serum BUN (p = 0.012) and creatinine (p = 0.018), SOD (p = 0.026), GSH (p = 0.012), and MDA (p = 0.011). Levosimendan significantly downregulated TNF-alpha (p = 0.022), NFK-ss (p = 0.008), and IL-6 (p = 0.033). Histopathological marks of hyaline and haemorrhagic cast were improved in levosimendan-injected groups. Conclusion Levosimendan showed nephroprotective properties due to its vasodilator, oxidative distress decreasing and inflammatory cytokine preventing belongings.en_US
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectContrast Mediaen_US
dc.subjectDrug-Related Side Effects and Adverse Reactionsen_US
dc.subjectIohexolen_US
dc.subjectLevosimendanen_US
dc.subjectRats (Wistar)en_US
dc.titleDoes the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?en_US
dc.typearticleen_US
dc.relation.ispartofEuropean Radiology Experimentalen_US
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyoloji Ana Bilim Dalıen_US
dc.authorid0000-0003-3122-4499en_US
dc.identifier.volume5en_US
dc.identifier.issue1en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1186/s41747-021-00249-7en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess